Madeline Lillie, MD
Allergy · Amherst, NYNPI 1962482711
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 773 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.
Across 773 payments — averaging $26.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$4K
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$3K
- GSK$3K
- CSL Behring$939
- Amgen$828
- plus $6K from 30 others
What the payments were for
- Consulting fees$1,3166%
- Food & beverage$19,23293%
- Education$1451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 86 | $4,032 |
| AstraZeneca | 121 | $3,208 |
| Regeneron Healthcare Solutions, Inc. | 103 | $3,098 |
| GSK | 130 | $2,537 |
| CSL Behring | 33 | $939 |
| Amgen(2 entities) | 37 | $828 |
| Pfizer | 37 | $797 |
| Genentech USA, Inc. | 26 | $730 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $576 |
| Kaleo, Inc. | 28 | $484 |
| Optinose US, Inc. | 18 | $462 |
| Alk-abello, Inc | 16 | $383 |
| Biocryst US Sales Co., LLC | 19 | $367 |
| Teva Pharmaceuticals USA, Inc. | 13 | $307 |
| Incyte Corporation | 6 | $223 |
| Novartis | 5 | $212 |
| Pharming Healthcare, Inc. | 7 | $212 |
| Grifols USA, LLC | 6 | $200 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $197 |
| Boehringer Ingelheim | 13 | $175 |
| Octapharma USA, Inc. | 5 | $111 |
| Blueprint Medicines Corporation | 5 | $109 |
| USWM, LLC | 4 | $86 |
| Shire North American Group Inc | 4 | $62 |
| Biocryst Pharmaceuticals, Inc. | 2 | $50 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
| Sanofi-aventis U.S. LLC | 1 | $44 |
| Phadia US Inc. | 2 | $41 |
| Galderma Laboratories, L.p. | 2 | $33 |
| Covis Pharma GmbH | 2 | $30 |
| Ionis Pharmaceuticals, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $22 |
| Cycle Pharmaceuticals Inc | 1 | $20 |
| Circassia Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Arcutis Biotherapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,692 in reported general payments places this provider in the 85th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 23 | $111,913 |
| XolairOmalizumab | 13 | $34,852 |
| Spiriva RespimatTiotropium Bromide | 22 | $21,718 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,615 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $11,635 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 58 | $11,356 |
| Epinephrine | 24 | $8,259 |
| Pulmicort FlexhalerBudesonide | 23 | $6,580 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $5,544 |
| Qvar RedihalerBeclomethasone Dipropionate | 14 | $5,286 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,200 |
| Azelastine Hcl | 170 | $4,113 |
| Fluticasone Propionate | 140 | $2,292 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 13 | $2,037 |
| Montelukast Sodium | 119 | $1,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat | $175 | $21,71822 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $2,537 | $19,81534 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $3,208 | $18,21555 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $307 | $5,28614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 92 allergy providers in New York.
Other allergy in Amherst
- Kathleen DonovanAmherst$16K
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
- Yudhistira PersaudBronx$127K
- Michael KatlanAlbany$91K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
- Alan KaufmanMount Vernon$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.